Drug Companies

World in turmoil, domestic pharma firms target India for healthy growth

Share of India revenue in home-grown firms' consolidated turnover rising over the years

CBI arrests Jt Drug Controller, Biocon Biologics execs over fishy approvals

All five apprehended will be presented in court on Tuesday afternoon, agency to seek police custody

India's major drug players bet on new brand launches, shows data

Industry insiders say brand launches are the lifeline of the pharma industry, and ensure steady volume growth and market share

Cipla Q3 PAT dips 2.6% at Rs 729 crore

Drug major Cipla on Tuesday reported a 2.6 per cent decline in its consolidated profit after tax to Rs 729 crore for the third quarter ended on December 31, 2021. The Mumbai-based company had posted a consolidated profit after tax (PAT) of Rs 748 crore in the October-December quarter of 2020-21 fiscal. Total revenue from operations, however, rose by 6 per cent to Rs 5,479 crore in the third quarter as compared with Rs 5,169 crore in the same period of last fiscal, Cipla said in a regulatory filing. "I am pleased to see the strong launch and commercial momentum across our core markets during the quarter. Our portfolio execution in branded markets of India and South Africa and strong respiratory traction driving our US generic franchise to a multi-quarter high quarter were key drivers," Cipla MD and Global CEO Umang Vohra noted. The unlocking of the company's first peptide asset, lanreotide injection is an important step in strengthening complex generics engine, inching up the drug .

Back to old normal: Pharma industry returns to pre-pandemic growth level

In this first instalment of a four-part series on how some of the defining numbers in key sectors are springing back to the pre-pandemic level, Sohini Das looks at India's pharmaceutical sector

PharmEasy acquires Medlife, becomes India's largest e-pharma company

As Medlife discontinues operations, its users will move seamlessly to Pharmeasy, which will now serve 2 million households every month

FabiFlu numero uno in Indian pharma market, show April sales data

With sales of Rs 352 crore in April, this brand alone accounted for over 2 per cent of the total domestic pharma market sales of Rs 15,662 crore

A bitter pill: Domestic pharma market growth slides to 1.1% in February

Recovery slow, top drug firms post muted growth in February

Coronavirus isn't going away soon, world must reset hopes for economy

For decades, the world economy relied on central bankers and finance ministers to pull it out of crisis

World Coronavirus Dispatch: Airlines urge mandatory tests to prop demand

Fujifilm to seek nod for Covid drug, UK economy faces gloomy fourth quarter, Deutsche Bank to close 100 retail branches and other pandemic-related news across the globe

CVS raises profit forecast, in talks with US to administer Covid vaccines

CVS also said it was working with laboratories to cut down the turnaround time for coronavirus test results, which had spiked in July due to a massive increase in demand for tests

Near-term hiccups to have limited impact on Abbott India's growth: Experts

Despite the muted result and near term worries, the multinational drug major, India's second largest by market share is expected to post strong growth led by power brands and new launches

Coronavirus impact: Govt keeps close tabs on drug supply, pricing

Govt keeping tabs on raw material stock, prices, and helping firms airlift APIs

Govt reviews industry's demands to implement changes in drug price policy

A senior government official said the industry has been requesting for an amendment to allow them to implement the price change from the next batch.

Drug firms rationalise portfolio, expect pricing pressure to ease in US

Drug makers are consolidating manufacturing facilities and rationalising their product portfolio in the US as they battle price erosion and weak profits

Vitamins drive drug launches

Drug companies are increasing their focus on the over-the-counter segment